This genetic fusion places ERG (and therefore ERG-regulated downstream target genes that control prostate cancer cell proliferation, differentiation and apoptosis) under androgen control—thus converting ERG into a hormone-responsive oncogene [6, 7]. The gene discussed is ERG; the disease is prostate carcinoma.